Publicacións en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (21)

2024

  1. Diagnóstico y tratamiento de los trastornos de la presión intracraneal: Documento de consenso del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología

    Neurologia

  2. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review

    Frontiers in Neurology , Vol. 15

  3. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  4. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

2023

  1. Diagnosis and treatment of trigeminal neuralgia: Consensus statement from the Spanish Society of Neurology's Headache Study Group

    Neurologia, Vol. 38, pp. S37-S52

  2. Recomendaciones de consenso para el tratamiento de la prevención de la migraña

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. 246-253

  3. Telemedicine in the management of patients with headache: current situation and recommendations of the Spanish Society of Neurology's Headache Study Group

    Neurologia, Vol. 38, Núm. 9, pp. 635-646

  4. [Translated article] Consensus recommendations on the preventive treatment of migraine

    Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. T246-T253

2022

  1. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  2. Cutaneous Allodynia in Migraine: A Narrative Review

    Frontiers in Neurology, Vol. 12

2021

  1. 1st Post-European Headache Federation Meeting: A review of the latest developments presented at the 2020 European Headache Federation Congress

    Revista de Neurologia

  2. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 21, Núm. 2, pp. 285-297

  3. Document of revision and updating of medication overuse headache (MOH)

    Neurologia, Vol. 36, Núm. 3, pp. 229-240

  4. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas

    Scientific Reports, Vol. 11, Núm. 1

  5. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

    Journal of Headache and Pain, Vol. 22, Núm. 1

  6. Neuromodulation in headache and craniofacial neuralgia: guidelines from the Spanish Society of Neurology and the Spanish Society of Neurosurgery

    Neurologia, Vol. 36, Núm. 1, pp. 61-79

  7. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

    Neurologia, Vol. 36, Núm. 8, pp. 611-617

2020

  1. Estimating the savings associated with a migraine-free life: results from the Spanish Atlas

    European Journal of Neurology, Vol. 27, Núm. 12, pp. 2616-2624

  2. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study

    European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108

  3. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578